Want to see OBIO full AI Analyst Report?
Total Valuation
Orchestra BioMed Holdings has a market cap or net worth of $238.92M. The enterprise value is $237.01M.
Market Cap$238.92M
Enterprise Value$237.01M
Share Statistics
Orchestra BioMed Holdings has 59,880,714 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding59,880,714
Owned by Insiders31.07%
Owned by Institutions28.15%
Financial Efficiency
Orchestra BioMed Holdings’s return on equity (ROE) is -0.83 and return on invested capital (ROIC) is -52.40%.
Return on Equity (ROE)-0.83
Return on Assets (ROA)-0.46
Return on Invested Capital (ROIC)-52.40%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee389.33K
Profits Per Employee-612.80K
Employee Count86
Asset Turnover0.29
Inventory Turnover0.61
Valuation Ratios
The current PE Ratio of Orchestra BioMed Holdings is ―. Orchestra BioMed Holdings’s PEG ratio is 0.18.
PE Ratio―
PS Ratio4.76
PB Ratio2.51
Price to Fair Value2.51
Price to FCF-3.22
Price to Operating Cash Flow-2.81
PEG Ratio0.18
Income Statement
In the last 12 months, Orchestra BioMed Holdings had revenue of 33.48M and earned -52.70M in profits. Earnings per share was -1.38.
Revenue33.48M
Gross Profit33.29M
Operating Income-51.81M
Pretax Income-52.70M
Net Income-52.70M
EBITDA-51.23M
Earnings Per Share (EPS)-1.38
Cash Flow
In the last 12 months, operating cash flow was -54.52M and capital expenditures -561.00K, giving a free cash flow of -55.08M billion.
Operating Cash Flow-54.52M
Free Cash Flow-55.08M
Free Cash Flow per Share-0.92
Dividends & Yields
Orchestra BioMed Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.87
52-Week Price Change31.68%
50-Day Moving Average4.01
200-Day Moving Average4.07
Relative Strength Index (RSI)47.61
Average Volume (3m)419.95K
Important Dates
Orchestra BioMed Holdings upcoming earnings date is Aug 18, 2026, Before Open (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
Orchestra BioMed Holdings as a current ratio of 6.45, with Debt / Equity ratio of 66.00%
Current Ratio6.45
Quick Ratio6.43
Debt to Market Cap0.09
Net Debt to EBITDA0.37
Interest Coverage Ratio-45.13
Taxes
In the past 12 months, Orchestra BioMed Holdings has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Orchestra BioMed Holdings EV to EBITDA ratio is -2.74, with an EV/FCF ratio of -2.84.
EV to Sales4.20
EV to EBITDA-2.74
EV to Free Cash Flow-2.84
EV to Operating Cash Flow-2.87
Balance Sheet
Orchestra BioMed Holdings has $94.40M in cash and marketable securities with $33.63M in debt, giving a net cash position of $60.77M billion.
Cash & Marketable Securities$94.40M
Total Debt$33.63M
Net Cash$60.77M
Net Cash Per Share$1.01
Tangible Book Value Per Share$1.65
Margins
Gross margin is 99.27%, with operating margin of -154.73%, and net profit margin of -157.40%.
Gross Margin99.27%
Operating Margin-154.73%
Pretax Margin-157.40%
Net Profit Margin-157.40%
EBITDA Margin-153.00%
EBIT Margin-153.97%
Analyst Forecast
The average price target for Orchestra BioMed Holdings is $11.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$11.40
Price Target Upside148.91% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast1033.89%
EPS Growth Forecast36.35%